Second Sight Medical Products (NASDAQ:EYES) announced its quarterly earnings results on Monday. The medical device company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.16), Fidelity Earnings reports. Second Sight Medical Products had a negative net margin of 994.14% and a negative return on equity of 183.76%.
EYES opened at $0.97 on Tuesday. The company has a quick ratio of 1.74, a current ratio of 1.88 and a debt-to-equity ratio of 0.33. Second Sight Medical Products has a 52 week low of $0.71 and a 52 week high of $8.96. The business’s fifty day simple moving average is $1.04 and its 200 day simple moving average is $2.50.
Several research firms have recently weighed in on EYES. Zacks Investment Research downgraded Second Sight Medical Products from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. HC Wainwright restated a “buy” rating and issued a $2.50 price target on shares of Second Sight Medical Products in a research report on Friday, March 20th. Finally, ValuEngine upgraded Second Sight Medical Products from a “hold” rating to a “buy” rating in a research report on Thursday, April 9th.
About Second Sight Medical Products
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
Read More: Compound Interest and Why It Matters When Investing
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.